On March 23, 2026, Jason A. Leverone, chief financial officer of OnKure Therapeutics, Inc. (NASDAQ: OKUR), completed a sale of 301 shares of the companys Class A common stock. The shares were disposed of at a weighted average price of $4.1565, producing total proceeds of $1,251. Reported transaction prices spanned from $3.995 to $4.235.
The sale was automatic and executed to satisfy tax withholding obligations connected to the vesting of restricted stock units granted under OnKures 2023 RSU Equity Incentive Plan. The transaction was recorded in a Form 4 filing with the Securities and Exchange Commission.
After the disposition, Leverone is listed as directly owning 16,000 shares of OnKure common stock. The company disclosure notes that a portion of those holdings are restricted stock units. Each restricted stock unit constitutes a contingent right to receive one share of Class A common stock, subject to the specific vesting schedule and conditions attached to each RSU award.
On the market, OnKures shares are trading at $3.98, which the company notes is an increase of 53% over the prior six-month period. The reported sale amount is modest relative to total outstanding shares and does not reflect an open-market decision beyond the tax-related automatic sale of vested awards.
Analyst update
In related market commentary, H.C. Wainwright revised its outlook on OnKure Therapeutics by lowering the stock price target to $27 from $34. The firm retained a Buy rating on the shares, attributing the target reduction to an anticipated equity raise expected in the second quarter of 2026.
H.C. Wainwrights note also referenced OnKures clinical progress. The companys lead investigational candidate, OKI-219, remains in Phase 1 testing with a focus on solid tumors. Those development activities are characterized by the company as part of its strategic priority to advance the pipeline.
Context and disclosure
The reporting filing and the analyst update are the primary sources for the transaction and the outlook change. The analysts decision to maintain a Buy rating was noted alongside the lowered price target, signaling continued conviction in the firms longer-term prospects despite the planned equity transaction cited by the firm.